Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer

93 patients with hormone refractory metastatic prostate cancer were entered on a prospective study to measure reduction in pain and changes in quality of life (QoL) after the administration of 150 MegaBequerel (MBq) Strontium-89 (Sr-89). QoL was assessed using a validated instrument, the Functional...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, S L, Gruenewald, S, Spry, N, Gebski, V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363737/
https://www.ncbi.nlm.nih.gov/pubmed/11161391
http://dx.doi.org/10.1054/bjoc.2000.1610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363737/
https://www.ncbi.nlm.nih.gov/pubmed/11161391
http://dx.doi.org/10.1054/bjoc.2000.1610

Ejemplares similares